A global campaign to fund the development of vaccines and therapies against COVID-19 has so far raised 9.5 billion euros ($10.4 billion), the head of the European Commission said.

With the COVID-19 pandemic closing physicians’ offices and causing patients to think twice about exposing themselves in healthcare settings, Neurocrine is delaying the company’s launch of Ongentysis.

Merck announced positive data from the Phase III KEYNOTE-355 trial looking at the company’s checkpoint inhibitor Keytruda (pembrolizumab) in combination with chemotherapy as a first-line treatment for metastatic triple-negative breast cancer.

The COVID-19 pandemic sparked national concern about vulnerabilities in the drug supply chain. Many drugs procured in the United States are manufactured abroad. The pandemic disrupted the production of key pharmaceutical ingredients around the world, sparking fear about resulting shortages of key medicines. The system also struggled to keep pace with rising demand for drugs to treat patients with COVID-19. During this webinar, panelists will explore the impact of the pandemic on different facets of the drug supply chain and discuss policy options to strengthen the system.

The World Health Organization said some treatments appear to be limiting the severity or length of the COVID-19 disease and that WHO was focusing on learning more about four or five of the most promising ones.

Despite the COVID-19 pandemic, the U.S. Food and Drug Administration has managed to stay fairly on track in terms of evaluating new drug and supplemental new drug applications. Here is a look at what is on the schedule for the next two weeks.

United Nations leaders called for a global effort to develop and distribute to all at affordable prices vaccines, treatments and testing kits against COVID-19.

Faster Drug Development Processes Likely to Outlive COVID-19 Published: April 30, 2020 By Gail Dutton BioSpace   The COVID-19 pandemic has increased the pace of drug development and regulatory approval dramatically, accelerating activities in ways that shorten the time needed to deliver safe, effective therapeutics, vaccines and diagnostics to patients. “It’s unfortunate it took a […]

Roche company Genentech presented one-year data from FIREFISH Part 2, a pivotal trial of risdiplam in infants one to seven months old with symptomatic Type 1 spinal muscular atrophy (SMA).

Numerous major global biopharma companies reported first-quarter 2020 earnings. Typically, the COVID-19 pandemic has affected the companies, although not necessarily in a straightforward way. Many of the companies reported increased sales for the quarter as customers increased stockpiles and inventory in preparation for the pandemic, while other forms of sales and clinical trials were negatively impacted. Here’s a look.